PDMS and PFO is effective as tamponade

Article

A study published in Clinical Ophthalmology has proved the efficacy of using polydimethyloxane (PDMS) and perfluoro-n-octane (PFO) as tamponade in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR).

A study published in Clinical Ophthalmology has proved the efficacy of using polydimethyloxane (PDMS) and perfluoro-n-octane (PFO) as tamponade in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR).

An investigation led by Dr Stefano Zenoni, Bergamno Hospital, Bergamo, Italy, aimed to evaluate ocular tolerance and efficacy of short-term tamponade with double-filling of PDMS and perfluoro-n-octane (PFO) in 30 patients. Double filling with 30% PFO and 70% PDMS was performed for a mean period of 23 days. Follow-up visits were scheduled for 1 week, 1 month and 3 months postoperatively. The main outcome measures included visual acuity, intraocular pressure (IOP), PVR reprofileration and electrophysiological parameters.

Of the 30 patients, 14 experienced improved postoperative visual acuity, 12 patients maintained preoperative visual acuity and 4 patients had a decrease in visual acuity. The average postoperative IOP was 19.7 mmHg. Nine patients experienced an increase in IOP, which was later treated with topical drops or systematic carbonic anhydrase.

Additionally, the researchers found a statistically significant difference in the data obtained with the electroretinogram (ERG) between week 4 and 8 of the follow-up period. There were no electroretinographic traces of retinal toxicity and there was a low occurrence of PVR reproliferation.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.